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Abstract 
The loss of wild type p53 tumor suppressive function and oncogenic gain-of-function of p53 
mutants have been showing important implications in tumorigenesis. The p53
N236S (p53
N239S in 
human, p53S) mutation has been shown to lose wild type p53 function by yeast assay. 
However, its gain of function is still not clear. By gel shift assay, we showed that mutant p53S 
had lost its DNA binding ability to its target promoters. Further real-time PCR data confirmed 
that p53S had lost the function of regulating the transcription of p21
 Cip1/Waf1, cyclin G, PUMA, 
and Bax in response to 10Gy irradiation. These data confirmed the loss of function of p53S in 
mammalian cells. By xenograft assay, we showed that the p53S per se was not oncogenic 
enough  to  form  tumor,  however,  cooperating  with  H-RasV12,  p53S  could  dramatically 
promote tumorigenesis in p53 null MEFs. Further study showed that co-expression of p53S 
and H-RasV12 could increase the expression level of H-RasV12 and partially eliminate the 
elevation of stress response proteins such as Chk2, γ-H2AX, Hsp70, Rb, p16
Ink4a caused by 
either p53S or H-RasV12. These data suggested that p53S cross-talked with H-RasV12 and 
reduced the cellular stress response to oncogenic signals, which facilitated the cell growth and 
tumorigenesis. Together these data provided the molecular basis for the cooperation of p53S 
and H-RasV12 and revealed the gain of function of p53S in cross-talking with H-RasV12. This 
study revealed an important aspect of gain of function for p53 mutant, therefore might shed 
light on the clinical strategy in targeting p53 mutant. 
Key words: p53 mutant, gain of function, Ras, tumorigenesis, DNA damage response, cross-talk. 
Introduction 
TP53 mutation is one of the most frequent muta-
tions occurred in human tumorigenesis. Interestingly, 
more than 80% of 26,608 tumor related mutations are 
point mutations (IARC TP53 database, version R15, 
November  2010)  [1].  Among  those,  seventy-three 
amino acids of p53 have been identified as hotspots 
for mutations found in human tumors by comparing 
the  observed  mutation  distribution  with  a  random 
multinomial  distribution  [2].  However,  it  has  been 
shown  that  p53  mutant  proteins  resulted  from  dif-
ferent site of p53 point mutations vary dramatically in 
terms of their loss of function and gain of function, as 
well as their oncogenic effects [3, 4].  
One of the current strategies in cancer treatment 
is trying to apply personalized treatment aiming dif-
ferent p53 mutants. Thus, understanding of the loss 
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and  gain  of  function  of  different  p53  mutants  will 
provide the basis for personalized treatments of can-
cer patients. 
A previous study showed that mouse embryonic 
fibroblasts (MEFs) from the late generation of Werner 
Syndrome  mice  (G5mTR-/-Wrn-/-)  senesced  very  rap-
idly, interestingly, the senescent MEF cells are prone 
to  escape  from  senescence  and  spontaneously  im-
mortalize. Injection of some of the immortalized cell 
lines into SCID mice result in tumorigenesis [5].  
When  we  compare  the  molecular  differences 
between these tumorigenic and non-tumorigenic cell 
lines, we found a single point mutation of p53 in all 
three independent tumorigenic cell lines, which cause 
one single amino acid change of N236S in mouse p53. 
The corresponding mutation in human p53 is N239S. 
The p53N239S mutation occurred at the L3 loop of DNA 
binding  domain.  This  region  is  highly  conserved 
among  different  species,  thus  might  play  an  im-
portant role in p53 function [2, 6]. IARC TP53 data-
base  (version  R14,  November  2009)  [1]  shows  that 
human  p53N239S  (or  p.N239S  )  has  been  reported  as  a 
somatic  mutation  in  32  tumor  cases,  tumor  origin 
tissues including breast, colon, stomach, hematopoi-
etic and reticuloendothelial systems, liver and intra-
hepatic bile ducts, bronchus and lung, and brain etc. 
The widespread tumor  spectrum  harboring p53N239S 
suggested its importance in tumorigenesis. Functional 
assays in yeast [7] and structure-function predictions 
[8] indicate that p53N239S is a non-functional mutation.  
However, very few studies have been done in 
mammalian  cells  for  p53N239S  function.  p53N239S  has 
been reported as one of the p53 mutations occurred in 
rheumatoid arthritis (RA) [9]. When p53N239S was in-
troduced into HS68 dermal fibroblasts together with 
wild type p53, it was able to up-regulate IL-6 expres-
sion  [10].  This  result  provided  the  evidence  for  the 
dominant negative function of p53N239S (Since there is 
endogenous  wild  type  p53).  However,  the 
gain-of-function of mutant p53N239S is not well under-
stood. The better understanding of gain of function of 
p53N239S mutant  will  benefit  the  cure  of  human  dis-
eases bearing this mutation. 
Here  by  using  non-tumorigenic  p53-/-  MEFs  as 
background,  we  characterized  the  loss  and  gain  of 
function  of  p53S.  Furthermore,  H-RasV12  were  in-
troduced  into  p53-/-  MEFs  with  or  without  p53S  to 
investigate the gain of function of p53S in cooperating 
with oncogenes.  
Results 
p53S mutant lost the DNA binding activity as 
well as the transactivation activity 
To  test  the  DNA  binding  activity  of  p53S,  gel 
shift assay was applied. Wild type p53 or p53S mutant 
proteins were obtained by in vitro translation to per-
form EMSA. The in vitro translated proteins were la-
beled  with  S35  and  their  input  in  EMSA  assay  was 
showed in Figure 1A, upper panel. Due to the non-
specific  in vitro  translated  protein  band  showing  in 
empty  vector  control  (Figure  1A,  upper  panel),  we 
performed super-shift assay to insure the specificity of 
EMSA. Specific antibodies to wild type p53 (Ab1) or 
p53S (Ab1 recognizing p53S and anti-cMyc recogniz-
ing  Myc  tag)  were  added  to  the  EMSA  reaction  to 
perform super-shift assay. The results revealed that 
p53S lost its binding activity to both p21 and PERP 
promoters (Figure 1A, lower panel), suggest p53S lost 
the function of regulating its down stream targets. 
Furthermore,  we  introduced  p53S  into  p53-/- 
MEFs and used this cell line (p53-/-+S) for testing p53S 
function  in  DNA  damage  response.  The  wild  type 
MEFs and immortalized cell line 395-3B-1 were used 
as controls. 
Since the control wild type MEF is not very sen-
sitive to radiation, we use 10Gy ionized radiation (IR) 
to challenge the cells. After 6 hr of the IR treatment, 
real-time PCR was performed to analyze p53S func-
tion  in  cell  cycle  arrest  or  apoptotic  pathways.  The 
expression levels of the four p53 down-stream targets, 
p21, cyclin G1, Puma and Bax, were examined to de-
termine  the  transactivation  activity  of  p53S  in  re-
sponse to IR. The results showed that unlike wild type 
p53, neither endogenous p53S from immortalized cell 
line 395-3B-1 nor ectopic expressed p53S in p53-/- MEF 
cells transactivated p21, cyclin G1, Puma and Bax in 
response to IR (Figure 1B).  
Together these data suggested that p53S lost its 
transcriptional regulatory function in both cell cycle 
arrest and apoptotic pathways, thus lost the function 
of inhibiting tumorigenesis. 
p53S mutant promoted cell growth and tu-
morigenesis in cooperating with H-RasV12 
 To  investigate  whether  p53S  per  se  is  tumor-
igenic, using the non-tumorigenic p53-/- MEFs as the 
background, we introduced p53S into p53-/- MEF cells 
together with or without H-RasV12.  
We found that, as previously reported [11], p53-/- 
MEFs did not form tumors by subcutaneously inject-
ing into SCID mice (data not shown), while overex-
pressing H-RasV12 in p53-/- MEFs (p53-/-+Ras) resulted 
in tumorigenesis in 2-3 weeks (Figure 2A, left middle 
panel). To our surprise, introducing of p53S into p53-/- 
MEFs (p53-/-+S) did not generate tumors either (Figure 
2A, left lower panel), suggesting that p53S per se is not 
enough to be tumorigenic. However, when we intro-
duced  p53S  together  with  H-RasV12  in  p53-/-  MEFs Int. J. Biol. Sci. 2012, 8 
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(p53-/-+S+Ras), fast growing tumors were generated in 
1-2 weeks (Figure 2A, left upper panel). The tumors 
harvested from p53-/-+S+Ras cells weighted 0.6500±
0.1323g, which is significantly bigger than the tumors 
harvested  from  p53-/-+vector+Ras  cells  (0.1650 ±
0.05315g). The P value is 0.014. These data strongly 
suggests a gain of function of p53S cooperating with 
H-RasV12 in tumorigenesis. Western blot revealed an 
elevated  H-RasV12  expression  in  the  SCID  tumors 
derived  from  p53-/-+S+Ras  cells  comparing  with  tu-
mors derived from p53-/-+vector+Ras cells (Figure 2B), 
which suggested a possible regulation of Ras expres-
sion by p53S. It has been shown that mutant p53 could 
alter its nuclear localization, and thus altered its func-
tion [12]. To understand whether Ras could also reg-
ulate p53S localization, immunostaining of p53 was 
performed. The results showed that p53S localized in 
the nuclei of both p53-/-+S and p53-/-+S+Ras cells (Fig-
ure 2C), the coexpression of H-RasV12 did not change 
the nuclear localization of p53S.  
 
 
Figure 1. Mutant p53S lost DNA-binding and transactivation activity. A: Upper panel: The in vitro translated proteins labeled by 
35S to show the input of protein amount in EMSA reactions. Empty vector was used as a control for in vitro translation. * Indicates the 
nonspecific protein band that appeared in the empty vector control. Lower panel: Super-shift gel images. To avoid nonspecific binding to 
the nonspecific band shown in the empty vector control, the super-shift in the EMSA was applied with an Ab1 antibody specific to p53 
proteins and an anti-cMyc antibody specific to p53S. The p53-specific DNA-binding activity to either PERP (left) or p21 (right) promoters 
only occurred in the wild-type p53 control (indicated by an arrow). p53S did not show specific binding to either PERP or p21 promoter 
DNA tested using two specific antibodies, Ab1 and anti-cMyc. * Indicates the non-specific shifted band caused by the protein shown in the 
empty vector control. B: Real-time PCR analysis showed that the transactivation activity of p53S for p21, cyclin G1, puma and Bax was 
disrupted in response to irradiation. The relative expression levels of p21, cyclin G1, puma and Bax were measured 6 hrs after exposure 
to 10 Gy irradiation. 
 Int. J. Biol. Sci. 2012, 8 
 
http://www.biolsci.org 
599 
 
Figure 2. p53S mutant promoted tumorigenesis cooperating with H-RasV12. A: In vivo tumorigenesis test by subcutaneously 
injecting cells into SCID mice. Left upper panel: p53-/-+S+Ras cells formed fast growing tumors in 1-2 weeks. Right upper panel: 
p53-/-+S+Ras tumors dissected from a SCID mouse. Left lower panel: p53-/-+vector+Ras cells formed tumors in 2-3 weeks. Right lower 
panel: p53-/-+vector+Ras tumors dissected from a SCID mouse. B: Western blotting analysis of p53S and Ras in the tumors in panel A. Ras 
expression was elevated in the SCID tumors derived from p53-/-+S+Ras cells comparing with the tumors derived from p53-/-+vector+Ras 
cells. C: Immunostaining of exogenous p53S in p53-/- MEFs with or without H-RasV12. The bar length is 50µm. D: Cytogenetic analysis 
revealed multiple chromosome aberrations in p53-/-+S+Ras, p53-/-+vector+Ras tumor cells and p53-/-+S MEFs. Left, arrows pointed to 
double minutes; middle & right, arrows pointed to chromosome fusions. The bar length is 10µm. 
 
 
It has been shown that p53 mutant gained the 
function  of  promoting  both  chromosome  instability 
and cell survival [13]. Furthermore, the amplification 
of  oncogenes  has  been  found  correlated  with  chro-
mosome instability, especially the increase of a spe-
cific  structure:  double  minute  chromosome  [14,  15]. 
Thus we performed cytogenetic analysis to investigate 
the effect of p53S on chromosome instability. Chro-
mosome analysis revealed multiple chromosome ab-
errations  in  p53-/-+S+Ras,  p53-/-+vector+Ras  tumor 
cells and p53-/-+S MEFs in contrast with p53-/- MEFs 
and wild type MEFs (Figure 2D, left, arrows pointed 
to double minutes. middle & right, arrows pointed to 
chromosome  fusions).  Among  these,  dramatically 
increased double minutes were found in p53-/-+S+Ras 
cells, which again implied the oncogenic characteris-
tics of p53S as well as the cross-talk between p53S and 
Ras. 
Furthermore,  to  understand  the  regulation  of 
p53S-Ras  in  cell  proliferation  or  apoptosis,  the 
p53-/-+S+Ras,  p53-/-+vector+Ras  tumor  cells  were 
measured for their proliferation and apoptosis status. 
Annexin V staining showed that both tumor cells had 
small  percentage  of  cells  in  apoptosis,  and 
p53-/-+S+Ras  had  less  apoptotic  cells  than 
p53-/-+vector+Ras  tumor  cells  (Figure  3A,  C).  Brdu 
incorporation  assay  revealed  that  both  p53-/-+S+Ras 
and p53-/-+vector+Ras had good percentage of prolif-Int. J. Biol. Sci. 2012, 8 
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erative cells, and p53-/-+S+Ras had a bit more prolif-
erative cells than p53-/-+vector+Ras tumor cells (Figure 
3B, C). These data suggested that p53S and H-RasV12 
cooperated to increase cellular proliferation and de-
crease  apoptosis,  thus  facilitated  the  tumor  growth. 
These  data  also  explained  the  fast  growing  tumors 
occurred  in  the  SCID  mouse  injected  with 
p53-/-+S+Ras cells.  
The molecular basis of the cooperation be-
tween p53S and H-RasV12 in promoting tu-
morigenesis 
To  understand  the  cell  cycle  regulation  by  the 
p53S or/and Ras, flow cytometry analysis was per-
formed. The data showed that p53-/-+S MEFs had sim-
ilar cell cycle pattern with wild type MEFs. However, 
both p53-/-+vector+Ras and p53-/-+S+Ras cells showed 
significant increase in S phase and decrease in G1/G0 
phase  comparing  with  p53-/-  cells  (Figure  4A).  Fur-
thermore,  less  p53-/-+S+Ras  cells  were  located  in 
G1/G0 phase and more in S phase comparing with 
p53-/-+vector+Ras cells (Figure 4A). This result further 
suggested  that  p53S  per se  is  not  advanced  in  pro-
moting  cell  growth,  however,  cooperating  with 
H-RasV12,  they  would  promote  cell  growth  greatly 
and facilitate tumorigenesis  
 
 
 
Figure 3. The apoptosis and proliferation rate in p53-/-+S+Ras and p53-/-+vector+Ras tumor cells. A: The cells were stained 
with Annexin-V and PI. The black arrows point to late stage apoptotic cells and the white arrows point to early stage apoptotic cells. DIC, 
differential interference contrast microscopic visual field. The bar length is 100µm. B: Cell proliferative status was measured by BrdU 
incorporation. C: The percentage of early stage apoptotic cells, late stage apoptotic cells and the BrdU-labeled proliferative cells. 
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Figure 4. The regulation of cell cycle and stress responses by p53S or/and H-RasV12. A. Cell cycle analysis by FACS revealed 
growth advantage from cooperation of p53S and H-RasV12. The percentage of sub G1, G1/G0, S, G2/M and super G2 were shown in 
sections  of  stacked bars.  B.  Western  blotting  analysis  of  protein  expression  profile  in  five  cell  lines:  p53-/-  MEFs,  p53-/-+S MEFs, 
p53-/-+vector+Ras tumor cells, p53-/-+S+Ras tumor cells and wild type MEFs (WT). Star showed the non-specific band for phosphorylated 
p53 blotting. 
 
To further dissect the molecular basis of the co-
operation  between  p53S  and  H-RasV12,  the  down-
stream proteins involved in gain of function of p53 
mutants were analyzed in four MEF cell lines: p53-/- 
MEFs,  p53-/-+S  MEFs,  p53-/-+vector+Ras  tumor  cells, 
p53-/-+S+Ras tumor cells. The wild type MEFs (WT) 
were used as the control.  
 We  found  that  either  introduction  of  p53S  or 
H-RasV12 in p53-/- cells resulted in the up-regulation 
of Chk2, Hsp70 and γ-H2AX, indicated that cellular 
DNA damage responses (DDR) could be initiated by 
p53S  or  H-RasV12  solo  overexpression  (Figure  4B, 
lane  p53-/-+S  and  lane  p53-/-+vector+Ras,  comparing 
with lane p53-/- ). It has been reported that oncogenic 
signals such as Ras could stimulate cellular DDR[16]. 
Here we showed that p53S could also stimulate DDR, 
suggesting that p53S gained oncogenic characteristics. 
At the same time, the cell cycle inhibitors p16Ink4a and 
Rb were also up-regulated by p53S or H-RasV12 solo 
overexpression  (Figure  4B,  lane  p53-/-+S  and  lane 
p53-/-+vector+Ras, comparing with lane  p53-/- ), sug-
gesting  the  p16Ink4a  -Rb  tumor  suppression  axis  re-
mained intact and could be activated by either p53S or 
H-RasV12 independent of wild type p53 function. 
Interestingly,  co-expression  of  p53S  and 
H-RasV12  partially  eliminated  the  up-regulation  of 
Chk2, Hsp70, γ-H2AX, p16Ink4a and Rb in response to 
solo expression of either p53S or H-RasV12 (Figure 4B, 
lane  p53-/-+S+Ras,  comparing  with  lane  p53-/-+S  and 
lane p53-/-+vector+Ras). These might contribute to the 
rapid cell cycle progression by co-expression of p53S 
or H-RasV12.  
As we have observed in the SCID tumor tissue 
(Figure 2B), the co-expression of p53S and H-RasV12 Int. J. Biol. Sci. 2012, 8 
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in p53-/- background resulted in an enhanced expres-
sion of H-RasV12 comparing with overexpression of 
H-RasV12 itself, provided us a direct evidence for the 
cooperation between p53S and H-RasV12 (Figure 4B, 
Ras).  
We also found that the expression of p19ARF was 
stimulated  by  either  p53S  or  H-RasV12  overexpres-
sion, which is consistent with the stress response of 
p19ARF  to  oncogenic  stimulations.  However,  under 
this genetic context (p53-/-+S or p53-/-+S+Ras), the only 
p53 proteins existed in the cells are mutant p53S. the 
stabilization  mechanism  of  p53  by  p19ARF  acted  on 
p53S  mutant  proteins,  which  further  stabilized  the 
protein level of p53S and facilitated the tumorigenesis 
(Figure 4B, p19 ARF).  
To further understand the effect of p53S-Ras on 
cellular  proliferation,  we  also  checked  the  level  of 
active Akt, which is known to be the down stream 
proliferation  molecule  of  Ras  pathway.  The  results 
revealed that total Akt level are not changed in the 
presence of p53S or H-RasV12 (Figure 4B, Akt). It is 
very  interesting  that  p53S  itself  could  increase  the 
level of  phosphorylated Akt:  pSer-473-Akt (Figure 4B, 
p53-/- +S), although not as great as H-RasV12 (Figure 
4B,  p53-/-  +Ras).  Since  the  induction  of  active  phos-
phorylated Akt is known as the downstream of Ras 
regulation, this data again suggested the Ras-like on-
cogenic property of p53S. However, when both p53S 
and H-RasV12 were present, the level of pSer-473-Akt 
decreased (Figure 4B, p53-/- +S+Ras). Giving the fact 
that  p53-/-+S+Ras  resulted  in  fast  growing  tumor 
(Figure 2A), we speculated that a balanced active Akt 
level (not too high, not too low) might be best for tu-
mor growth. 
Together  these  data  suggested  that  the  p53S 
cross-talk with H-RasV12, reduced the cellular stress 
response to oncogenic signals, and promoted the pro-
liferative  potential,  which  facilitate  the  cell  growth 
and tumorigenesis. 
Discussion 
The  current  strategies  in  cancer  treatment  are 
trying  to  apply  personalized  treatment  aiming  dif-
ferent  p53  mutants.  Understanding  of  the  loss  and 
gain of function of different p53 mutants provides the 
basis for personalized treatments.  
Seventy-three  amino  acid  of  p53  have  been 
identified as hotspots for mutations found in human 
tumors by comparing the observed mutation distri-
bution with a random multinomial distribution. N239 
is one of the medium hot spots (p < 0.01) located at the 
protein surface involving in DNA interaction [2]. A 
study  in  yeast  classified  N239S  as  one  of  the 
non-discriminant p53 mutants that are unable to dis-
criminate between different p53 responsive elements 
[17]. By assessment of its transactivation capacities in 
yeast  assays  [7],  N239S  was  classified  as  a 
non-functional  mutant.  The  computational  analysis 
and yeast assays also suggested that N239S mutation 
located in the loop region of the DNA binding domain 
is a mild mutation comparing to those mutations lo-
cated  in  the  helix  or  β-sheet  region  of  the  DNA 
binding domain. Despite of these predictions, N239S 
somatic mutations were found in 32 cases of human 
tumors [1], suggesting its important function in hu-
man tumorigenesis.  
In this study, we showed by EMSA that the p53S 
lost its DNA binding ability to promoters regulated by 
wild type p53. Real-time PCR analysis confirmed that 
p53S lost the function in regulating the transcription 
of p21 Cip1/Waf1, cyclin G, PUMA, and Bax in response 
to 10Gy irradiation. These results suggested that p53S 
lost the function of wild type p53 in regulating cell 
cycle arrest and apoptosis, thus lost the ability of tu-
mor  suppressing.  Our  data  confirmed  the  loss  of 
function  of  p53S  in  mammalian  cells  with  p53  null 
background. 
Previous  study  has  showed  that  different  p53 
point mutations varied dramatically in their impacts 
on p53 function [4]. The mutation occurred at amino 
acid N239 is a good example. A substitution mutation 
N239Y has been found to facilitate in restoring tran-
scriptional activity in a subset of cancer mutants, in-
cluding V143A, G245S and R249S [18]. N239Y muta-
tion could stabilize the p53 protein and rigidify the 
local structure without perturbing it [19, 20]. Moreo-
ver, a very recent study showed that N239Y mutant 
was more active than wild-type p53 in terms of Bax 
transcription and apoptotic activity, which correlated 
very well with its structure stability [21]. Thus it is 
very important to understand the gain of function of 
each mutant. 
Our  data  revealed  that  p53S  cross-talked  with 
H-RasV12 and gain new functions in promoting tu-
morigenesis.  It  has  been  shown  that  activated  Ras 
could induce the accumulation of p53, p21, p16Ink4a, 
and p14/p19ARF, decrease expression of cyclin A, and 
reduce kinase activity of CDK2 [22, 23], thus initiate 
signaling transduction to cellular senescence. Further 
study  revealed  that  Ras-initiated  DNA  replication 
forks  could  serve  as  effective  DNA  damage  signals 
and induced DNA damage response, which resulted 
in cellular senescence [16]. These data clearly showed 
that the oncogenic effect of Ras is highly dependent 
on  the  dysfunction  of  intact  cellular  DNA  damage 
response pathway, especially, p53 status. Loss of p53 
function  removes  the  barrier  for  oncogenic  growth 
signals, which passively cooperates with Ras. Recent Int. J. Biol. Sci. 2012, 8 
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researches  found  that  p53  inactivation  induced  the 
RasV12  pathway  through  diverse  mechanisms  in-
volving the p53 targets BTG2 and ATF3, which in turn 
facilitated  the  malignant  transformed  phenotype  of 
cells and the accentuated expression of chemokines, 
CXCL1;  interleukins,  IL-1 β ;  ECM-related  genes, 
MMP3  [24].  These  data  revealed  the  cancer-related 
gene  signatures,  which  underlies  the  cross-talk  be-
tween the p53 tumor suppressor and Ras oncogene. 
It  has  reported  that  concomitant  endogenous 
expression of Trp53(R172H) and K-Ras(G12D) to the 
mouse pancreas caused cooperative development of 
invasive and widely metastatic carcinoma [25], sug-
gested that p53 mutant could actively cooperate with 
Ras in tumorigenesis. The frequent occurrence of both 
p53 & Ras mutation in human tumors also suggest the 
active interaction between them.  
Here we showed that the p53N239S actively coop-
erated with H-RasV12 and facilitated tumorigenesis in 
xenografted mice. We found that in molecular level, 
p53S  could  promoted  the  expression  of  H-RasV12. 
This effect suggested that p53S could directly or in-
directly regulate the transcription of H-RasV12. We 
are working on CHIP assay to reveal possible targets 
for p53S binding, the results might reveal the mecha-
nism underlying Ras regulation by p53S. 
Furthermore, we found that in p53-/- background, 
introduction  of  p53S  could  stimulate  the  DDR  re-
sponse, as suggested by the up-relation of γ-H2AX, 
Chk2,  p19,  p16Ink4a,  and  HSP70,  similar  to  the  re-
sponses to H-RasV12. Either H-RasV12 or p53S could 
stimulate  the  response  of  p16Ink4a-Rb  pathway,  but 
together they deregulated these responses, thus could 
reduce  the  inhibition  of  cell  cycle  and  promote  tu-
morigenesis. These data revealed the Ras-like onco-
genic properties of p53S, it is reasonable to speculate 
that p53S could also stimulate the growth signals in 
cells, thus promoting tumorigenesis. Supporting this, 
we found that either p53S or H-RasV12 could induce 
the level of phosphorylated Akt (pSer-473-Akt), which is 
an important down stream proliferative signal for Ras 
pathway  [26].  Interestingly,  when  both  p53S  and 
H-RasV12  were  present,  the  level  of  pSer-473-Akt  de-
creased. Giving the fact that p53-/-+S+Ras resulted in 
fast  growing  tumor,  we  speculated  that  a  balanced 
active Akt level (not too high, not too low) might be 
best for tumor growth. It has been found that active 
Akt could  increase the cellular ROS level thus pro-
moting  cellular  senescence  in  wild  type  MEFs  [27]. 
This  finding  suggests  that  active  Akt  plays  an  im-
portant role in homeostatic regulation of cell viability 
[28]. Our data is consistent with this hypothesis.  
Together these data explained the molecular ba-
sis for the fast tumorigenesis in the cells co-expressing 
p53S  and  H-RasV12  and  strongly  indicated  the 
cross-talk between p53S and H-RasV12. 
It is worth to notice that p53N239S has also been 
found  in  rheumatoid  arthritis  synovial  tissue  and 
synoviocytes,  possibly  involved  in  positively  inter-
fering immune system by regulating the IL-6 produc-
tion, suggesting its role in RA pathogenesis [10].  
To  further  understand  the  function  of  p53S, 
knock-in  p53N236S  mouse  model  will  be  utilized  to 
clarify its role in aging-related mesenchymal tumor-
igenesis, as well as RA.  
Conclusions 
Our data confirmed the loss of function of p53S 
mutant in mammalian cells. More importantly, these 
data  revealed  the  Ras-like  oncogenic  properties  of 
p53S  and  suggested  that  p53S  cross-talked  with 
H-RasV12 and reduced the cellular stress response to 
oncogenic  signals,  which  facilitated  the  cell  growth 
and tumorigenesis. This study revealed an important 
aspect of gain of function for p53 mutant, therefore 
might shed light on the clinical strategy in targeting 
p53 mutant. 
Materials and Methods 
Cell lines and constructs 
All  cell  lines  were  cultured  in  DMEM  supple-
mented with 10% fetal bovine serum (Hyclone, CA) in 
3% oxygen and 5% CO2 incubator at 37°C.  
 p53S cDNA fragment was cloned from immor-
talized cell line 395-3B-1 by RT-PCR and put into ret-
roviral vector PQCXIP and PQCXIH (Clontech, CA), 
tagged  with  cMyc  peptide.  The  sequence  was  con-
firmed by sequencing and the expression of the con-
structed p53S-cmyc was confirmed by Western blot-
ting.  
Either empty vector PQCXIH or PQCXIH-p53S 
construct or pBabe-H-RasV12 construct (as described 
previously [22]) were introduced into p53-/- MEF. Af-
ter 1-2 months antibiotics selection, cell colonies were 
picked up, expression of p53S or H-RasV12 was ana-
lyzed by both Western blotting and immunostaining. 
By this way, p53-/- MEFs stably introduced both p53S 
and H-RasV12 (p53-/-+S+Ras MEFs), or H-RasV12 and 
empty  PQCXIH  vector  (p53-/-+vector+Ras  MEFs),  or 
p53S only ( p53-/-+S MEFs ) were established. 
To detect stress response, cells were treated with 
10Gy  ionized  irradiation.  Six  hours  after  treatment, 
cells were harvested for further experiments. 
Antibodies 
Antibodies used for Western blotting were an-
ti-Chk2  (1:500,  BD  Transduction  Laboratories,  CA), Int. J. Biol. Sci. 2012, 8 
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anti-Rb  (1:500,  BD  Transduction  Laboratories,  CA), 
anti-Ras  (1:500,  BD  Transduction  Laboratories,  CA), 
anti-cMyc (9E10) (1:500, Santa Cruz, CA), anti- p16Ink4a 
(M-156) (1:500, Santa Cruz, CA), anti- p21 (F-5) (1:500, 
Santa Cruz, CA), anti-p53 Ab1(clone PAb240) (1:250, 
Neomarker,  CA),  anti-phospho-p53  (Ser15)  (1:500, 
Cell  Signaling,  MA),  anti-Hsp70  (1:1000,  Stressgen, 
Canada), anti-Hsp90 (1:1000, Stressgen, Canada), an-
ti-PCNA (1:1000, Upstate, NY), anti-p19 (1:1250, Up-
state, NY), anti-γ-H2AX  (1:1000, Upstate, NY), an-
ti-γ-tubulin (1:5000, Upstate, NY). 
Elecrophoretic mobility shift assay (EMSA) 
 The ability of p53S to bind DNA was tested us-
ing  EMSA  modified  from  a  previously  described 
protocol  [29].  Briefly,  pcDNA3  empty  vector, 
pcDNA3-p53 or pcDNA3-p53S-myc were used for in 
vitro translation (TNT® T7 Coupled Reticulocyte Ly-
sate  System,  Promega,  WI)  to  provide  wild-type  or 
mutant  p53S  protein  for  use  in  the  EMSA  reaction. 
The protein input level was checked by  35S labeling. 
p21 and PERP promoter oligonucleotides (sequences 
are  as  previously  described  [30])  were  synthesized 
and labeled with 32P-γ-ATP. The EMSA reaction was 
performed in a buffer containing 10 mM Tris-HCl (pH 
7.5), 50 mM KCl, 5 mM MgCl, 0.5 mM EDTA, 1 mM 
DTT,  10%  glycerol,  and  0.45  μg/μl  salmon  sperm 
DNA. EMSA products were separated on a 4-20% 1x 
TBE gel (Invitrogen, CA). The super-shift was done by 
adding  either  p53  antibody  Ab1  (PAb421,  Calbio-
chem, NJ) or anti-cMyc antibody (Santa Cruz, CA). 
Real-time RT-PCR 
 RNA was extracted from cells 6 hrs after expo-
sure to 10 Gy irradiation and was reverse transcribed 
to  cDNA.  Real-time  PCR  was  performed  using  a 
SYBR-Green PCR master mix according to the manu-
facturer’s instructions (Applied Biosystems, CA). The 
primers used were as follows: p21 (Forward primer: 5' 
CCA GGC CAA GAT GGT GTC TT 3', Reverse pri-
mer: 5' TGA GAA AGG ATC AGC CAT TGC 3'), Cy-
clin G (Forward primer: 5' CCG GTC CGT GAC GCC 
3', Reverse primer: 5' AGT TCA ACA ATC CGA AAA 
GCT GA 3'), Bax (Forward primer: 5' GTT TCA TCC 
AGG ATC GAG CAG 3', Reverse primer: 5' CCC CAG 
TTG AAG TTG CCA TC 3'), puma (Forward primer: 
5´ GTA CGG GCG GCG GAG ACG AG 3', Reverse 
primer: 5´ GCA CCT AGT TGG GCT CCA TTT CTG 
3'), and GAPDH (Forward primer: 5' TCA CCA CCA 
TGG AGA AGG C 3', Reverse primer: 5' GCT AAG 
CAG TTG GTG GTG CA 3') [31-34].  
Injection of cells into SCID mice and tumor 
cells harvest 
 1x  106  cells  were  injected  subcutaneously  into 
each site of SCID mice. When the size of the largest 
tumor reached 1 cm, the mice were sacrificed and the 
tumors  were  collected  and  digested  in  a  tumor  di-
gesting cocktail (4 mg/ml collagenase D and 4 mg/ml 
dispase II). Isolated tumor cells were plated and cul-
tured in DMEM supplemented with 10% fetal bovine 
serum. All mouse procedures were performed with 
the approval of the Animal Care and Use Committee 
of the Kunming University of Science & Technology 
(approval ID: M2009-011). 
Cytogenetics analysis 
Metaphase  chromosomes  from  cells  were  pre-
pared  as  described  [35]  and  subjected  to  Giemsa 
staining.  About  30  metaphases  from  each  sample 
were analyzed in detail. 
Cell cycle analysis 
Cell cycle analysis was done by flow cytometry 
(BD,  FACS  Vantage  SE).  Data  were  analyzed  by 
Flowjo.  Percentages  of  cells  in  G1,  S,  and  G2  were 
determined using the Dean-Jett-Fox algorithm.  
Annexin V staining and BrdU incorporation 
Annexin  V  staining  was  performed  with  the 
Annexin V-FLUOS staining kit (Roche, Germany) to 
detect apoptotic cells. The stained cells were analyzed 
by fluorescence microscopy. The early stage apoptotic 
cells only showed Annexin V positive staining, and 
the  late  stage  apoptotic  or  dead  cells  showed  both 
Annexin V and propidium iodide positive staining. 
The apoptotic cells are counted and the apoptosis rate 
were calculated. BrdU incorporation was performed 
with the In Situ cell proliferation kit FLUOS (Roche, 
Germany)  according  to  the  manufacturer’s  instruc-
tions.  Briefly,  cells  were  labeled  with  BrdU  (final 
concentration:  10  μM)  for  1  hr  and  immunostained 
with anti-BrdU-FLUOS antibody. The BrdU incorpo-
ration  rate  was  measured  by  counting  cells  labeled 
with anti-BrdU antibody. 
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